An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.
Would the AMG 531 be something you would recommend to a young lady in childbearing ages wanting to persue fertility in hopes to become pregnant? Is this a better option than having the spleen removed?